Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Iovance Biotherapeutics Shares Are Soaring Today

By Keith Speights - Nov 8, 2019 at 11:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news from the biotech's mid-stage clinical study is exciting investors.

What happened

Shares of Iovance Biotherapeutics ( IOVA 2.30% ) were soaring 12.5% higher as of 11:27 a.m. EST on Friday. The nice jump came after the biotech announced updated data from a phase 2 clinical study evaluating lifileucel in treating metastatic melanoma. These results, presented at the Society for Immunotherapy of Cancer (SITC) annual meeting, included findings that patients receiving lifileucel in the second cohort of the study experienced an objective response rate (ORR) of 35% and that the median duration of response was not reached after 11.3 months into the study.

So what

You can look at Iovance's latest news in two ways. If you're the kind of person who sees a glass of water as half full, the updated phase 2 results should make you more optimistic than ever about the prospects for lifileucel. The experimental drug is one of two pipeline candidates that Iovance is evaluating in pivotal studies. Anything that could potentially improve the likelihood of eventual FDA approval for either of these drugs is very good for Iovance.

Scientists in a lab.

Image source: Getty Images.

What if you're the kind of person who sees the glass as half empty? You'll probably focus on the fact that the latest results were only preliminary and only for one cohort in the phase 2 study. It's not out of the question at all for a drug to have some promising preliminary results only to stumble later.

In reality, both perspectives are good ones. It makes sense that Iovance shares would jump on today's announcement. The updated results truly are positive. It also makes sense that many investors would remain cautious about banking too heavily on early results for an unproven drug.

Now what

Iovance CEO Maria Fardis said that the company plans to continue enrolling patients in the pivotal cohort of the phase 2 study of lifileucel. She added that data from this cohort should be the basis for Iovance's anticipated FDA filing for approval of the drug late next year.

Investing in biotech stocks, especially clinical-stage biotechs like Iovance, comes with plenty of excitement. But that excitement can sometimes be short-lived. The potential for lifileucel in treating metastatic melanoma is promising, but there's still a long way to go.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Iovance Biotherapeutics, Inc. Stock Quote
Iovance Biotherapeutics, Inc.
IOVA
$16.93 (2.30%) $0.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
633%
 
S&P 500 Returns
140%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.